Horizon Medical Products, Inc. Announces the Launch of Its Newest Port.

Business Editors/Health/Medical Writers

ATLANTA--(BUSINESS WIRE)--Nov. 25, 2003

Horizon Medical Products, Inc. (AMEX:HMP) today announced the launch of the Triumph(TM) VTX(R) Port with LifeValve(R) Platinum catheter. Ports are used for the long-term infusion of chemotherapy, nutrition, antibiotics and for blood and blood sampling.

"It is the natural extension for the LifeValve(R) Platinum catheter technology to be combined with our Vortex(R) port lines," said Marshall Hunt, Chairman and CEO. "This product is part of an on going, dedicated effort to solve problems for both the patient and clinician. In this case, patients will receive all of the fluid dynamic benefits of the Vortex(R) technology with the added benefit of the new LifeValve(R) catheter technology. The desired result is significantly reduced clotting caused by inadvertent blood backflow into the catheter for improved reliability."

The first of the LifeValve(R) Platinum product family was the central venous catheter (CVC), which launched in August of 2003. LifeValve(R) Platinum gets its name from the embedded platinum band that provides improved visibility during placement. The LifeValve(R) Platinum products have a pressure sensitive valve that is designed to only open during clinical use.

"A valve that opens only during clinical use helps protect the patient from an air embolism and reduces inadvertent blood backflow. Since the LifeValve(R) products do not require the use of heparin we believe that clinical costs will be reduced. Additionally, heparin-optional devices, such as this Triumph(TM) Vortex (R) Port, may be used on patients with heparin sensitivity. Ultimately, our hope is that this marriage of these exciting new technologies will result in better patient outcomes," concluded Hunt.

ABOUT HORIZON MEDICAL PRODUCTS

Horizon Medical Products, Inc. headquartered in Atlanta, is a world leader in design, development, manufacture and sale of technologically advanced, high value-added, percutaneous vascular and spinal access systems. The Company's oncology product lines include implantable ports, some of which feature its proprietary VTX(R) technology; tunneled central venous catheters; and stem-cell transplant catheters used primarily in cancer treatment protocols. The Company also markets a complete line of acute and chronic dialysis catheters. In June 2003, the Company gained exclusive U.S. rights to distribute Medtronic Inc.'s Hepatic Arterial Infusion (HAI) product line, including sales and case support of Medtronic's IsoMed(R) Infusion System and related products. Its Internet address is www.hmpvascular.com.

SAFE HARBOR

Certain statements and information included herein may constitute "forward-looking statements" which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on current expectations and may be significantly impacted by certain risks and uncertainties described herein and various documents filed by the Company with the U.S. Securities and Exchange Commission, including but not limited to the Company's Prospectus on Form S-1 and the Company's Annual Report on Form 10-K for the year ended December 31, 2002 and the Company's Quarterly Reports on Form 10-Q. There can be no assurances that statements made in this press release relating to future events will be achieved. The Company undertakes no obligations to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time.